NCIC Clinical Trials Group

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Observation or Radical Treatment in Patients With Prostate Cancer

Not Applicable

Terminated

Conditions: Prostate Cancer

Interventions: Procedure: conventional surgery
Radiation: brachytherapy
Radiation: external beam radiation therapy
Procedure: Biopsies

First Posted Date: 2007-07-11

Last Posted Date: 2023-08-23

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 180

Registration Number: NCT00499174

Locations: 🇨🇦
Ottawa Health Research Institute - General Division, Ottawa, Ontario, Canada
🇨🇦
QEII Health Sciences Center, Halifax, Nova Scotia, Canada
🇨🇦
Odette Cancer Centre, Toronto, Ontario, Canada

and more 10 locations

Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2007-06-05

Last Posted Date: 2024-02-12

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 4

Registration Number: NCT00482755

Locations: 🇨🇦
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
Edmond Odette Cancer Centre at Sunnybrook, Toronto, Ontario, Canada

OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors

Phase 1

Completed

Conditions: Breast Cancer
Kidney Cancer
Bladder Cancer
Ovarian Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Lung Cancer
Prostate Cancer

First Posted Date: 2007-05-10

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 40

Registration Number: NCT00471432

Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Non-Hodgkins Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: Aurora kinase inhibitor AT9283

First Posted Date: 2007-03-07

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 35

Registration Number: NCT00443976

Locations: 🇨🇦
Ottawa Health Research Institute - General Division, Ottawa, Ontario, Canada
🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada

Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: bortezomib
Drug: cyclophosphamide
Drug: prednisone
Drug: vincristine sulfate

First Posted Date: 2007-01-29

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 95

Registration Number: NCT00428142

Locations: 🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇨🇦
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
Humber River Regional Hospital, Toronto, Ontario, Canada

and more 16 locations

AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: CDKI AT7519
Other: laboratory biomarker analysis

First Posted Date: 2006-10-19

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 34

Registration Number: NCT00390117

Locations: 🇨🇦
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2006-10-13

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 32

Registration Number: NCT00387400

Locations: 🇨🇦
McGill University - Dept. Oncology, Montreal, Quebec, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

and more 6 locations

Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: bortezomib
Drug: gemcitabine hydrochloride

First Posted Date: 2006-09-15

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 29

Registration Number: NCT00377052

Locations: 🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇨🇦
Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada
🇨🇦
Odette Cancer Centre, Toronto, Ontario, Canada

and more 8 locations

AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2006-09-07

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 27

Registration Number: NCT00372736

Locations: 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
McGill University - Dept. Oncology, Montreal, Quebec, Canada
🇨🇦
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

AEG35156 and Docetaxel in Treating Patients With Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: AEG35156
Drug: docetaxel

First Posted Date: 2006-07-27

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 10

Registration Number: NCT00357747

Locations: 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
McGill University - Dept. Oncology, Montreal, Quebec, Canada

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy